Under the agreement, AbbVie will grant Mylan a nonexclusive license to sell its drug in the United States and in other markets outside of Europe. The US license term for the biosimilar will start on July 31, 2023, and Mylan will pay royalties on its sales to AbbVie.
Drug maker AbbVie, sponsor of the top-selling adalimumab (Humira), has settled with a third biosimilar developer seeking to launch a competitive product.
AbbVie announced Tuesday morning that it has reached a patent license agreement with biosimilar developer Mylan over an as-yet unapproved adalimumab molecule.
Under the agreement, AbbVie will grant Mylan a nonexclusive license to sell its drug in the United States and in other markets outside of Europe. The US license term for the biosimilar will start on July 31, 2023, and Mylan will pay royalties on its sales to AbbVie.
Notably, no deal was announced concerning marketing of an adalimumab product in the European Union, where the European Medicines Agency is actively reviewing the proposed adalimumab biosimilar FKB327, developed by Fujifilm Kyowa Kirin Biologics and slated to be commercialized by Mylan. A regulatory decision on FKB327 is expected before the end of this year.
The US settlement follows similar settlements between AbbVie and biosimilar developers; in April 2018, the Humira maker announced a deal with Samsung Bioepis and Biogen concerning Imraldi, an adalimumab biosimilar that is approved in the European Union, although it has not yet been approved by the FDA. Under the terms of the Samsung Bioepis and Biogen deal, AbbVie will grant patent licenses for the product in Europe on a country-by-country basis beginning on October 16, 2018. In the United States, should the drug be approved, the partnership will be permitted to market the biosimilar beginning on June 30, 2023.
Earlier, in September 2017, Amgen announced that it had reached a deal with AbbVie that would allow it to launch its biosimilar, Amgevita, in the European Union on October 16, 2018, and in the United States (under the slightly different name Amjevita) on January 31, 2023.
Today’s deal comes as AbbVie faces increased scrutiny of such settlements; this month, US Senators Chuck Grassley, R-Iowa, and Amy Klobuchar, D-Minnesota, urged the Federal Trade Commission (FTC) to investigate whether settlements over Humira or other high-cost biologic drugs are “pay-for-delay” tactics that keep consumers from accessing cheaper biosimilars in a timely way. Also calling on the FTC to investigate AbbVie’s settlements is the patient advocacy group Patients for Affordable Drugs, which has called the deals anticompetitive.
AbbVie has objected to characterizations of its settlements as “pay-for-delay” tactics, saying that “AbbVie is not paying Amgen or Samsung Bioepis, and in fact both Amgen and Samsung Bioepis will be paying royalties to AbbVie once their adalimumab biosimilar products launch in the [United States].”
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).